Perot Systems Posts Net Income Of $28 Million In Q1 2009
Business Outlook For the second quarter of 2009, the company expects earnings per share to range between $0.23 and $0.25 and revenue to range from $620 million to
Voro Therapeutics and Alloy Therapeutics have formed a strategic research partnership to develop tumour-selective, next-generation masked T-cell engager (TCE) therapeutics.